10x Genomics, Inc.

NasdaqGS:TXG Voorraadrapport

Marktkapitalisatie: US$2.1b

10x Genomics Dividenden en inkoop

Dividend criteriumcontroles 0/6

10x Genomics heeft geen dividenduitkeringen gedaan.

Belangrijke informatie

n/a

Dividendrendement

-0.6%

Terugkoop Rendement

Totaal aandeelhoudersrendement-0.6%
Toekomstig dividendrendement0%
Dividendgroein/a
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeeln/a
Uitbetalingsration/a

Recente updates van dividend en inkoop

Geen updates

Recent updates

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

10x Genomics: Deciphering The Preliminary Q3 Earnings

Oct 12

The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

Oct 11
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van TXG in het verleden stabiel is geweest.

Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van TXG zijn gestegen.


Dividendrendement versus markt

10x Genomics Dividendrendement versus markt
Hoe verhoudt TXG dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (TXG)n/a
Markt onderkant 25% (US)1.4%
Markt Top 25% (US)4.3%
Gemiddelde industrie (Life Sciences)0.5%
Analist prognose (TXG) (tot 3 jaar)0%

Opmerkelijk dividend: Het dividendrendement van TXG kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.

Hoog dividend: Het dividendrendement van TXG kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.


Winstuitkering aan aandeelhouders

Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio TXG te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat TXG geen uitbetalingen heeft gerapporteerd.


Ontdek bedrijven met een sterk dividend